Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Shimpei Maeda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9344-6527; OpenAlex author ID A5023578535, A5101517570, A5124942943, A5128889017. Sources: OpenAlex.

Their work

Papers
28 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
83
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 4 papers · 2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: 6 papers · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 4 papers

Papers 28

  1. Histological treatment response to neoadjuvant chemotherapy predicts the survival outcomes of patients with resectable pancreatic cancer: validation of the Jap… Co-author DOI 10.1007/s00595-026-03325-w↗
  2. Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: a propensity s… Co-author DOI 10.1016/j.gassur.2026.102358↗
  3. SMAD3 activation in pancreatic stellate cells correlates with PTGDR2 expression and favorable stromal features in pancreatic cancer. Co-author DOI 10.1016/j.pan.2026.03.007↗
  4. Predictive Factors for Occult Metastases in Clinically M0 Pancreatic Cancer: A Prospective Multicenter Analysis of Staging Laparoscopy. Co-author DOI 10.1245/s10434-026-20728-8↗
  5. Preoperative Chemotherapy With Gemcitabine for Pancreatic Cancer Causes Zinc Deficiency. Co-author DOI 10.1097/mpa.0000000000002396↗
  6. Local Recurrence and Survival Outcomes after Portal Vein/Superior Mesenteric Vein Separation without Resection Preceding Neoadjuvant Therapy for Pancreatic Duc… Co-author DOI 10.1097/mpa.0000000000002503↗
  7. Clinical and pathological factors associated with survival in patients with pancreatic cancer who receive adjuvant therapy after neoadjuvant therapy: A retrosp… First author DOI 10.1016/j.surg.2024.01.008↗
  8. Deep learning predicts the 1-year prognosis of pancreatic cancer patients using positive peritoneal washing cytology. Co-author DOI 10.1038/s41598-024-67757-5↗
  9. CA19-9 With Two-stage Resection Is Useful for Conversion Surgery in PDAC With Synchronous Oligometastases. Co-author DOI 10.21873/anticanres.16724↗
  10. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Co-author DOI 10.1016/j.surg.2021.10.015↗
  11. Disease-related protein co-expression networks are associated with the prognosis of resectable node-positive pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-022-19182-9↗
  12. Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases. Co-author DOI 10.1007/s00595-020-02121-4↗
  13. Prognostic value of an inflammation-based nutritional score for patients with initially unresectable pancreatic adenocarcinoma undergoing conversion surgery fo… Co-author DOI 10.1007/s00595-021-02279-5↗
  14. Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer. Co-author DOI 10.1038/s41598-021-86099-0↗
  15. Ral GTPase-activating protein regulates the malignancy of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.14970↗
  16. Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up… Co-author DOI 10.1245/s10434-021-09718-0↗
  17. Stomatin‑like protein 2 induces metastasis by regulating the expression of a rate‑limiting enzyme of the hexosamine biosynthetic pathway in pancreatic cancer. Co-author DOI 10.3892/or.2021.8041↗
  18. Prognostic indicators in pancreatic cancer patients undergoing total pancreatectomy. Co-author DOI 10.1007/s00595-019-01924-4↗
  19. Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.08.022↗
  20. Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. Co-author DOI 10.1016/j.surg.2019.12.008↗
  21. Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment. Co-author DOI 10.21037/atm.2019.10.91↗
  22. 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s11605-017-3627-3↗
  23. Predictive risk factors for peritoneal recurrence after pancreatic cancer resection and strategies for its prevention. Co-author DOI 10.1007/s00595-017-1531-9↗
  24. Locally advanced pancreatic cancer successfully treated by distal pancreatectomy with celiac axis resection (DP-CAR) after S-1 with radiation therapy followed … Co-author DOI 10.1186/s40792-017-0290-6↗
  25. A long-term survival case treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver m… Co-author DOI 10.1186/s40792-017-0409-9↗
  26. [Multidisciplinary Therapy with Gemcitabine and Nab-Paclitaxel for Unresectable Pancreatic Cancer]. Co-author PMID 29394594↗
  27. Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded t… Co-author DOI 10.1002/ijc.27797↗
  28. Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. Co-author DOI 10.1007/s10147-011-0220-8↗

Closest collaborators

The 25 strongest of 83 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michiaki Unno · 24 shared papers, 2011–2026 · strength 2.91
  2. Masamichi Mizuma · 19 shared papers, 2017–2026 · strength 2.50
  3. Shuichi Aoki · 10 shared papers, 2020–2026 · strength 1.71
  4. Fuyuhiko Motoi · 16 shared papers, 2011–2026 · strength 1.56
  5. Masahiro Iseki · 9 shared papers, 2017–2026 · strength 1.53
  6. Kyohei Ariake · 14 shared papers, 2017–2026 · strength 1.43
  7. Kei Nakagawa · 13 shared papers, 2017–2025 · strength 1.39
  8. Daisuke Douchi · 6 shared papers, 2023–2026 · strength 1.20
  9. Mitsuhiro Shimura · 5 shared papers, 2017–2026 · strength 0.95
  10. Tatsuyuki Takadate · 12 shared papers, 2011–2022 · strength 0.93
  11. Takanori Morikawa · 11 shared papers, 2011–2021 · strength 0.90
  12. Takashi Kokumai · 4 shared papers, 2021–2025 · strength 0.64
  13. Shingo Yoshimachi · 4 shared papers, 2020–2026 · strength 0.64
  14. Koetsu Inoue · 3 shared papers, 2023–2026 · strength 0.60
  15. Timothy R. Donahue · 4 shared papers, 2020–2026 · strength 0.60
  16. Mark D. Girgis · 4 shared papers, 2020–2026 · strength 0.60
  17. Zev A. Wainberg · 3 shared papers, 2022–2026 · strength 0.51
  18. Keith D. Lillemoe · 3 shared papers, 2022–2026 · strength 0.51
  19. Atsushi Masamune · 2 shared papers, 2026 · strength 0.49
  20. Toru Furukawa · 2 shared papers, 2024–2026 · strength 0.40
  21. Takayuki Shimizu · 2 shared papers, 2024–2026 · strength 0.39
  22. Jason M. Link · 2 shared papers, 2024–2026 · strength 0.39
  23. Aya Noguchi · 2 shared papers, 2024–2025 · strength 0.35
  24. Motaz Qadan · 2 shared papers, 2022–2026 · strength 0.34
  25. Oscar Joe Hines · 2 shared papers, 2022–2026 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.